Recent Updates
Recently added Catalysts
ATYR Negative Sentiment Score: 20/100

ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that aTyr Pharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Key Takeaway: A class action lawsuit has been filed against aTyr Pharma, Inc. by Bronstein, Gewirtz & Grossman LLC, alleging violations of federal securities laws. The lawsuit concerns statements made about the drug Efzofitimod during the Class Period from January 16, 2025, to September 12, 2025. Plaintiffs claim that the company misled investors regarding the drug's effectiveness and concealed critical adverse facts, resulting in artificially inflated share prices. Investors have until December 8, 2025, to join the lawsuit.

Market Sentiment Analysis

CONCERNS & RISKS

  • A class action lawsuit has been filed against aTyr Pharma for alleged violations of federal securities laws.
  • The lawsuit alleges that the company made materially false and misleading statements about the efficacy of Efzofitimod.
  • Defendants are accused of concealing the drug's true capabilities, leading to inflated securities prices.

Full Press Release Details

NEW YORK, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against aTyr Pharma, Inc. (“aTyr” or “the Company”) (NASDAQ: ATYR) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired aTyr securities between January 16, 2025 and September 12, 2025, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/ATYR.
The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: (1) Defendants provided overwhelmingly positive statements to investors regarding the efficacy of Efzofitimod; (2) At the same time, Defendants disseminated false and misleading statements and/or concealed material adverse facts concerning the drug’s actual capability—particularly its ability to enable patients to completely taper their steroid usage; and (3) As a result of these omissions and misrepresentations, Plaintiff and other shareholders purchased aTyr’s securities at artificially inflated prices.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/ATYR. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in aTyr you have until December 8, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as lead plaintiff.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

Tags

Frequently Asked Questions

What is the aTyr Pharma class action lawsuit about?

The lawsuit claims aTyr Pharma made false statements and failed to disclose adverse facts about its drug Efzofitimod during the Class Period.

Who can join the aTyr Pharma class action?

Investors who purchased aTyr securities from January 16 to September 12, 2025, can join.

Is there any cost to participate in the lawsuit?

There is no cost to you; the firm operates on a contingency fee basis.

How do I become a lead plaintiff?

You must request to be appointed as lead plaintiff by December 8, 2025.

How can I contact Bronstein, Gewirtz & Grossman?

You can contact them at 332-239-2660 or via email at info@bgandg.com.

Last updated: Nov 7, 2025